COST EFFECTIVENESS OF ANTI-PD-1/PD-L1 TREATMENTS: SYSTEMATIC REVIEW OF PUBLISHED STUDIES

被引：0
|
作者：
Aggarwal, S. [1 ]
Topaloglu, O. [1 ]
Kumar, S. [2 ]
机构：
[1] NOVEL Hlth Strategies, Chevy Chase, MD USA
[2] Inst Global Policy, Washington, DC USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.187
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN110
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [41] High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
    Sanchez-Magraner, Lissete
    Miles, James
    Baker, Claire L.
    Applebee, Christopher J.
    Lee, Dae-Jin
    Elsheikh, Somaia
    Lashin, Shaimaa
    Withers, Katriona
    Watts, Andrew G.
    Parry, Richard
    Edmead, Christine
    Lopez, Jose Ignacio
    Mehta, Raj
    Italiano, Antoine
    Ward, Stephen G.
    Parker, Peter J.
    Larijani, Banafshe
    CANCER RESEARCH, 2020, 80 (19) : 4244 - 4257
  • [42] Comparison the results from PD-L1 IHC and PD-L1 multiplex immunofluorescence for the prediction of anti-PD-1 immunotherapeutic response
    Sun, Hongzhe
    Liu, Xia
    Jiao, Tao
    Guo, Qian
    Du, Haizhen
    Han, Shuo
    Zhu, Lin
    Zhang, Zhifu
    Kong, Yan
    Li, Na
    CANCER RESEARCH, 2024, 84 (06)
  • [43] Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy
    Zhulai, Galina
    Oleinik, Eugenia
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2022, 95 (03)
  • [44] Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
    Song, Mengjia
    Chen, Xinfeng
    Wang, Liping
    Zhang, Yi
    CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (02) : 157 - 172
  • [45] DNA DAMAGE RESPONSE ALTERATIONS PREDICT RESPONSES TO ANTI-PD-1/PD-L1
    不详
    CANCER DISCOVERY, 2018, 8 (05) : 527 - 527
  • [46] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
    Chen, Lieping
    Han, Xue
    JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09): : 3384 - 3391
  • [47] Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy
    Cao, Yiyi
    Li, Wenbo
    Wang, ZhengJie
    Pang, Hua
    TUMORI JOURNAL, 2021, 107 (04): : 282 - 291
  • [48] Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer
    Ri, Myong Hak
    Ma, Juan
    Jin, Xuejun
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 281
  • [49] The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
    Wu, Dawei
    Huang, Huiyao
    Zhang, Minghui
    Li, Ziwei
    Wang, Shuhang
    Yu, Yue
    Fang, Yuan
    Jiang, Ning
    Miao, Huilei
    Ma, Peiwen
    Tang, Yu
    Li, Ning
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [50] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345